FDA Approves ASCENIV™ (formerly referred to as RI-002), A Novel Intravenous Immune Globulin
See the Press Release
ADMA Biologics is a biopharmaceutical company relentlessly committed to creating superior products for immunodeficient patients at risk for infection. It is our devotion to this underserved population that fuels us, and our hands-on approach to production and development that sets us apart.
ADMA Biologics Announces Commercial Relaunch and its First Commercial Sales of BIVIGAM®
ADMA Biologics Announces Commercial Relaunch and its First Commercial Sales of BIVIGAM®:READ MOREADMA Biologics Reports Second Quarter and First Half 2019 Financial Results
ADMA Biologics Reports Second Quarter and First Half 2019 Financial Results:READ MOREADMA Biologics Receives FDA Approval for License Transfers for BIVIGAM® and Nabi-HB®
ADMA Biologics Receives FDA Approval for License Transfers for BIVIGAM® and Nabi-HB®:READ MORE